Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GAD-alum + vitamin d
- Development stage
- Phase 2
- Lead developer
- Diamyd Medical
- Modality
- Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intralymphatic, Oral, Subcutaneous
01
Overview
GAD-alum + vitamin d is a combination therapy consisting of aluminum-formulated glutamic acid decarboxylase (GAD65) administered via intralymphatic injection together with oral supplementation of vitamin D. The primary mechanism is antigen-specific immunomodulation aimed at preserving endogenous insulin secretion in patients with recent-onset type 1 diabetes. GAD-alum acts as an autoantigen to induce immune tolerance against pancreatic beta cell antigens, while vitamin D is thought to have additional immunomodulatory effects that may enhance the efficacy of antigen-specific therapy. This combination has been studied primarily in individuals carrying the HLA DR3-DQ2 haplotype and has shown potential for disease modification by preserving C-peptide levels in this genetically defined subgroup[1][2][5].
- Brand names
- Diamyd + vitamin d
- Other names
- glutamic acid decarboxylase alum-adsorbed + vitamin dGAD65-alum + vitamin dintralymphatic GAD-alum with oral vitamin D
02
Targets
VDR (Vitamin D receptor)GAD2 (Glutamic Acid Decarboxylase 65)
Beyond the preview
Go deeper on GAD-alum + vitamin d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAD-alum + vitamin d.